Literature DB >> 17639294

[New methods of patient selection for improved anticholinergic therapy].

J Neuhaus1, T Schwalenberg, N Schlichting, M Schulze, L-C Horn, J-U Stolzenburg.   

Abstract

BACKGROUND: M3-specific inhibitors are currently preferred for anticholinergic therapy of OAB. However, not all of the patients profit from this regimen. This might reflect a heterogeneity of the patient group. The aim of this work is to define subgroups of patients with specific alterations of receptor expression and to profile the receptor expression individually. These receptor profiles might be used for the development of evidence-based "tailored" therapies. PATIENTS AND METHODS: Detrusor probes from bladder carcinoma patients (BCa, n=9 F, n=7 male) and interstitial cystitis patients (IC, n=9 female) were examined using confocal immunofluorescence and PCR.
RESULTS: M2, M3, P2X1-3, and H1-3 mRNAs were demonstrated in detrusor tissue. As revealed by immunofluorescence, the M2 receptor expression was significantly higher in female compared to male BCa tissues. In addition, the M2 receptor was further upregulated in IC vs BCa in female detrusor.
CONCLUSIONS: IC patients showed specific alterations of their receptor profile. Individual receptor profiles might be used to optimize medicinal therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17639294     DOI: 10.1007/s00120-007-1481-8

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  6 in total

1.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

2.  Prevalence and incidence of interstitial cystitis in a managed care population.

Authors:  J Quentin Clemens; Richard T Meenan; Maureen C O'Keeffe Rosetti; Sara Y Gao; Elizabeth A Calhoun
Journal:  J Urol       Date:  2005-01       Impact factor: 7.450

Review 3.  Role of muscarinic receptor antagonists in urgency and nocturia.

Authors:  Martin C Michel; Jean J M C H de la Rosette
Journal:  BJU Int       Date:  2005-09       Impact factor: 5.588

Review 4.  Interstitial cystitis.

Authors:  Ehab Kelada; Amanda Jones
Journal:  Arch Gynecol Obstet       Date:  2006-09-22       Impact factor: 2.344

5.  Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins.

Authors:  P Wang; G R Luthin; M R Ruggieri
Journal:  J Pharmacol Exp Ther       Date:  1995-05       Impact factor: 4.030

6.  M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. I. Normal rat bladder.

Authors:  Alan S Braverman; Amit S Tibb; Michael R Ruggieri
Journal:  J Pharmacol Exp Ther       Date:  2005-10-21       Impact factor: 4.030

  6 in total
  1 in total

1.  New aspects in the differential diagnosis and therapy of bladder pain syndrome/interstitial cystitis.

Authors:  Jochen Neuhaus; Thilo Schwalenberg; Lars-Christian Horn; Henry Alexander; Jens-Uwe Stolzenburg
Journal:  Adv Urol       Date:  2011-10-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.